Processa Pharmaceuticals Inc. reported a net loss of $13.6M for the year ended December 31, 2025, with $11.4M in net cash used in operating activities and $5.5M in cash and cash equivalents.
Bullish
Processa Pharmaceuticals Inc. is advancing NGC-Cap in Phase 2 with high potency and PCS12852 in Phase 2A with positive results, leveraging its Regulatory Science Approach to reduce clinical and regulatory risks.
Bearish
Processa Pharmaceuticals Inc. faces substantial doubt about its ability to continue operations due to recurring losses and significant cash burn, compounded by reliance on third-party manufacturers and digital asset volatility.